The combination of cyclophosphamide plus interferon beta as rescue therapy could be used to treat relapsing-remitting multiple sclerosis patients: Twenty-four months follow-up

Journal of Neurology

Volumn 252, Issue 10, 2005, Pages 1255-1261

  Reggio, Ester ^a   Nicoletti, Alessandra ^a   Fiorilla, Teresa ^a   Politi, Guido ^a   Reggio, Arturo ^a   Patti, Francesco ^a  

^a UNIVERSITY OF CATANIA   (Italy)

Author keywords

Combination therapy; Cyclophosphamide; Multiple sclerosis; Relapsing remitting

Indexed keywords

BETA1A INTERFERON; CYCLOPHOSPHAMIDE; INTERFERON BETA SERINE;

ADULT; AMENORRHEA; ARTICLE; BRAIN RADIOGRAPHY; CLINICAL ARTICLE; CONTROLLED STUDY; DATA ANALYSIS; DISEASE COURSE; DRUG EFFICACY; DRUG INDUCED HEADACHE; FEMALE; FOLLOW UP; HEMORRHAGIC CYSTITIS; HUMAN; MALE; MULTIPLE SCLEROSIS; NAUSEA; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; RECORDING; RECURRENCE RISK; SCORING SYSTEM; STATISTICAL SIGNIFICANCE; TREATMENT FAILURE; TREATMENT OUTCOME; URINARY TRACT INFECTION;

ADJUVANTS, IMMUNOLOGIC; ADOLESCENT; ADULT; CLINICAL TRIALS; CYCLOPHOSPHAMIDE; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INTERFERON-BETA; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; RECURRENCE; TIME FACTORS; TREATMENT OUTCOME;

EID: 26644463420     PISSN: 03405354     EISSN: 14321459     Source Type: Journal    
DOI: 10.1007/s00415-005-0857-1     Document Type: Article

References (41)

1. Carter JL, Hafler DA, Dawson DM, Orav J, Weiner HL (1988) Immunosuppression with high-dose IV cyclophosphamide and ACTH in progressive multiple sclerosis: cumulative 6-years experience in 164 patients. Neurology 38:9-14
2. Edan G, Miller D, Clanet C, Confavreux C, Lyon-Caen O, Lubetzki C, Brochet B, Berry I, Rolland Y, Froment JC, Dousset V, Cabanis E, Iba-Zizen MT, Gandon JM, Lai HM, Moseley I, Sabouraund O (1997) Therapeutic effect of mitoxantrone combined with methylprednisolone in multiple sclerosis: a randomised multicenter study of active disease using MRI and clinical criteria. J Neurol Neurosurg Psychiatry 62:112-118
3. Elison GW, Myers LW (1978) A review of systemic nonspecific immunosuppressive treatment of multiple sclerosis. Neurology 28:132
4. Gobbini MI, Smith ME, Richert ND, Frank JA, Mc Fahrland HF (1999) Effect of open label pulse cyclophosphamide therapy on MRI measures of disease activity in five patients with refractory relapsing-remitting multiple sclerosis. J Neuroimmunol 99:142-149
5. Gonsette R, Demonty L, Delmonte P (1977) Intensive immunosuppression with cyclophosphamide in multiple sclerosis: follow-up of 110 patients for 2-6 years. J Neuroimunol 214:173-181
6. Goodkin DE, Plencer S, Palmer SJ, Teetzen M, Hartsgaard D (1987) Cyclophosphamide in chronic progressive multiple sclerosis: maintenance vs nonmaintenance therapy. Arch Neurol 44:823-827
7. Hafler DA, Weiner HL (1995) Immunological mechanisms and therapy in multiple sclerosis. Immunol Rev 144:75-107
8. Hauser S, Dawson DM, Lehrich JR, Beal Mf, Kevy SV, Propper RD, Mills JA, Weiner HL (1983) Intensive immunosuppression in progressive multiple sclerosis: A randomised, three-arm study of high dose intravenous cyclophosphamide, plasma exchange and ACTH. N Engl Med 1983:173-180
9. Hommes OR, Lamers KJB, Reekers P (1980) Effect of intensive immunosuppression on the course of chronic progressive multiple sclerosis. J Neurol 223:177-190
10. IFNB MS Study Group (1993) Interferon beta-1b is effective in relapsing remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial The IFNB Multiple Sclerosis Study Group. Neurology 43:655-661
11. Interferon beta-1b and secondary progressive multiple sclerosis: licence and extension (2000) Useful, but further assessment required. Prescrire Int 9(48):110-111
12. Jacobs LD, Cookfair DL, Rudick RA, et al. (1996) Intramuscular interferon beta-1a for disease progression in relapsing remitting multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG). Ann Neurol 39(3):285-294
13. Johnson KP, Brooks BR, Cohen JA, Ford CC, Goldstein J, Lisak RP, Myers LW, Panitch HS, Rose JW, Schiffer RB, Vollmer T, Weiner LP, Wolinsky JS; Copolymer 1 Multiple Sclerosis Study Group (1998/2001) Extended use of glatiramer acetate (Copaxone) is well tolerated and maintains its clinical effect on multiple sclerosis relapse rate and degree of disability. Neurology 57(12 Suppl 5):S46-S53
14. Kahn OA, Zvartau-Hind M, Caon C, Din MU, Cochran M, Lisak D, Tselis AC, Kamholz JA, Garben JV, Lisak RP (2001) Effects of monthly intravenous cyclophosphamide in rapidly deteriorating multiple sclerosis patients resistant to conventional therapy. Mult Scler 7:185-188
15. Kallen B, Dohlsten M, Klementsson H (1986) Effect of cyclophosphamide pretreatment on autoimmune encephalomyelitis in rats. Acta Neurol Scand 73(4):338-344
16. Kappos L, Heun R, Mertens HG (1990) A 10 years matched-pairs study comparing azathioprine and no immunosuppression in multiple sclerosis. Eur Arch Psychiatry Neurol Sci 240:34-38
17. Kappos L (1988) Clinical trials of immunosuppression and immunomodulation in multiple sclerosis. J Neuroimmunol 20:216-268
18. Karussis DM, Slavin S, Ben-Nun A, Ovadia H, Vourka-Karussis U, Lehmann D, Mizrachi-Kol R, Abramsky O (1992) Chronic-relapsing experimental autoimmune encephalomyelitis (CR-EAE): treatment and induction of tolerance, with high dose cyclophosphamide followed by syngeneic bone marrow transplantation. J Neuroimmunol 39(3):201-210
19. Langford CA, Klippel JH, Balow JE, James SP, Sneller MC (1998) Use of cytotoxic agents and cyclosporine in the treatment of autoimmune disease. Part 1: Rheumatologic and renal diseases. Ann Intern Med 128(12):1021-1028
20. Langford CA, Klippel JH, Balow JE, James SP, Sneller MC (1998) Use of cytotoxic agents and cyclosporine in the treatment of autoimmune disease. Part 2: Inflammatory bowel disease, systemic vasculitis, and therapeutic toxicity. Ann Intern Med 129(1):49-58
21. Likosky WH (1988) Experience with cyclophosphamide in multiple sclerosis: the cons. Neurology 38(Suppl. 7):14-18
22. Lisak RP (1988) Overview of the rationale for immunomodulating therapies in multiple sclerosis. Neurology 38 (Suppl. 2):5-8
23. Mancardi GL, Saccardi R, Filippi M, et al. (2001) Autologus hemopoietic stem cell transplantation suppresses Gd-enhanced MRI activity in MS. Neurology 57:62-68
24. Martin R, Mc Farland HF, Mc Farln DE (1992) Immunological aspects of demyelinating diseases. Ann Rev Immunol 10:153-187
25. McDonald WI, Compston A, Edan G, Goodkin D, Hartung HP, Lublin FD, McFarland HF, Paty DW, Polman CH, Reigold SC, Sandberg-Wollheim M, Sibley W, Thompson A, Van den Noort S, Weinshenker BY, Wolinsky JS (2001 ) Recommended diagnostic criteria for multiple sclerosis: guidelines for the international Panel on the diagnosis of multiple sclerosis. Ann Neurol 50(1):121-127
26. Minagawa H, Takenaka A, Itoyama Y, Mori R (1987) Experimental allergic encephalomyelitis in the Lewis rat. A model of predictable relapse by cyclophosphamide. J Neurol Sci 78(2):225-235
27. Ormerod IE, Miller DH, Mc Donald WI, et al. (1987) The role of MRI imaging in the assessment of multiple sclerosis and isolated neurological lesions. A quantitative study. Brain 110:1579-1616
28. Patti F, Amato MP, Filippi M, Gallo P, Trojano M, Comi GC (2004) A double blind, placebo-controlled, phase II, add-on study of cyclophosphamide (CTX) for 24 months in patients affected by multiple sclerosis on a background therapy with interferon-beta study denomination: CYCLIN. J Neurol Sci 223(1):69-71
29. Patti F, Cataldi ML, Nicoletti F, Reggio E, Nicoletti A, Reggio A (2001) Combination of cyclophosphamide and interferon β halts progression in patients with rapidly transitional multiple sclerosis. J Neurol Neurosur Psychiatry 71:404-407
30. Patti F, Reggio E, Palermo F, Fiorilla T, Politi G, Nicoletti A, Reggio A (2004) Stabilization of rapidly worsening multiple sclerosis for 36 months in patients treated with interferon beta plus cyclophosphamide followed by interferon beta. J Neurol 251(12):1502-1506
31. Perini P, Marangoni S, Tzinteva F, Ranzato F, Tavolato B, Gallo P (2001) Two years therapy of secondary progressive multiple sclerosis (SPMS) with pulse intravenous cyclophosphamide/methylprednisolone. Clinical and MRI data. Mult Scler 7:S62
32. Poser CM, Paty DW, Scheinberg L, McDonald WI, Davis FA, Ebers GC, Johnson KP, Sibley WA, Silberberg DH, Tourtellotte WW (1983) New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol 13(3):227-231
33. PRISMS (Prevention of Relapses and Disability by interferon-beta 1a Subcutaneously in Multiple Sclerosis) Study Group (1998) Randomized double-blind, placebo-controlled study of interferon beta 1a in relapsing-remitting multiple sclerosis. Lancet 352:1498-1504
34. Smith D (2004) Preliminary analysis of a trial of pulse cyclophosphamide in IFN-beta-resistant active MS. J Neurol Sci 223(1):73-79
35. The Canadian Cooperative Multiple Sclerosis Study Group (1991) The Canadian cooperative trial of cyclophosphamide and plasma exchange in progressive multiple sclerosis. Lancet 337:441-446
36. Weiner HL, Cohen JA (2002) Treatment of multiple sclerosis with cyclophosphamide: critical review of clinical and immunologic effects. Mult Scler 2:142-154 (Review)
37. Weiner HL, Hafler DA (1988) Immunotherapy of multiple sclerosis. Ann Neurol 23:211-222
38. Weiner HL, Mackin GA, Ovar EJ, et al. (1993) Intermittent cyclophosphamide pulse therapy in progressive multiple sclerosis: final report of the Northeast Cooperative Multiple Sclerosis Treatment Group. Neurology 43:910-918
39. Weinstock-Guttman B, Kinkel RP, Cohen JA, et al. (1997) Treatment of "transitional MS" with cyclophosphamide and methyl-prednisolone (CTX-MP) followed by interferon β (abstract). Neurology 48(Suppl 2):A341
40. Zephir H, de Seze J, Duhamel A, Debouverie M, Hautecoeur P, Lebrun C, Malikova I, Pelletier J, Senechal O, Vermersch P (2004) Treatment of progressive forms of multiple sclerosis by cyclophosphamide: a cohort study of 490 patients. J Neurol Sci 218(1-2):73-77
41. Zephir H, De Seze J, Senechal O, Stojkovic T, Ferriby D, Deliss B, Dubus B, Verier A, Hautecoeur P, Vermersch P (2002) Traitement des formes progressives de sclerose en plaques par la cyclophosphamide. Rev Neurol (Paris) 158(1):65-69